The results of a preclinical study of the drug "Cytovir-3" were

By decision of the Ministry of HEALTH No. 20-3-4144274 / ID / IZM, changes were made to the instructions for medical use of the antiviral drug "Tsitovir-3", indicating that the drug "Tsitovir-3" has specific activity against the covid-19 pathogen. The "Pharmacological properties" section now contains information about the inhibitory effect of the drug on the reproduction of the SARS-COV-2 virus, which is the causative agent of the new CORONAVIRUS infection - COVID-19. The evaluation of the antiviral properties of the drug was performed using a special cell culture standardized for these studies. Under laboratory conditions, it has been proven that Cytovir-3 specifically inhibits the reproduction of the SARS-CoV-2 virus and reduces its activity. Extrapolation of these data to the whole organism suggests that the use of the drug will reduce the viral load, which will help prevent the development of the disease or reduce the severity of its course. The study showed that with an increase in the dose of the drug, the degree of inhibition of the coronavirus increases.

The data obtained as a result of this study can serve as the basis for the development of new or optimization of existing schemes for the treatment and prophylactic use of the drug when planning subsequent clinical trials to evaluate the effectiveness of the drug "Citovir-3", as for emergency - in the first hours after infection with the SARS virus -CoV-2 (in contact with a patient), as well as planned prevention (during the entire epidemic season), as well as for early etiopathogenetic treatment of various categories of patients with respiratory nosology, including COVID-19.

According to the interim guidelines of the Ministry of Health of the Russian Federation, taking into account the similarity of the clinical picture of mild forms of COVID-19 with the clinical picture of seasonal acute respiratory viral infections, the treatment regimens should include drugs recommended for the treatment of seasonal acute respiratory viral infections, such as intranasal forms of interferon alfa, interferon inducer preparations, as well as antiviral drugs with a wide spectrum of activity.

Cytovir-3 activates the mechanisms of innate immunity in cells, and also regulates the level of pro-inflammatory activity, protecting the body from the development of excessive immune inflammation, which develops especially often with influenza and other infections (in particular, COVID-19). According to clinical studies, it has a significant therapeutic and prophylactic efficacy, which is manifested in a decrease in the incidence rate, a reduction in its duration, as well as a significant decrease in the frequency of severe and protracted and complicated forms of influenza and SARS. "Citovir-3" eliminates the main symptoms of viral infections, increases the local resistance of the mucous membranes to bacteria and other infectious agents, in general, normalizes the reactions of the innate and T-cell immunity in response to the invasion of the virus. Clinical practice confirms

A source